+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Biopsy Forceps Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 186 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083678
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Biopsy Forceps Market grew from USD 234.78 million in 2025 to USD 249.36 million in 2026. It is expected to continue growing at a CAGR of 6.20%, reaching USD 357.78 million by 2032.

An authoritative orientation to the evolving biopsy forceps landscape shaped by clinical priorities sterilization practices and supply chain resilience

The landscape for biopsy forceps has evolved from a largely commoditized medical device category into a strategic component of diagnostic and therapeutic workflows across multiple specialties. Increasing procedural volumes, heightened clinical emphasis on procedural precision, and the drive to reduce cross-contamination risk have converged to raise the profile of device selection and procurement decisions. Consequently, device manufacturers, hospital procurement teams, and distribution partners are navigating an environment where clinical efficacy, sterilization workflow compatibility, and total cost of ownership play equal roles in purchasing decisions.

As clinical teams pursue minimally invasive diagnostics and adopt advanced endoscopic platforms, the technical characteristics of forceps-jaw design, material composition, and compatibility with visualization systems-have become differentiators. Meanwhile, regulatory scrutiny on single-use disposables and reusable device reprocessing has intensified, prompting manufacturers to refine labeling, sterilization guidance, and traceability features. In parallel, supply chain resilience and channel optimization have emerged as operational priorities, driven by recent global disruptions that highlighted dependencies in raw materials and manufacturing footprints.

Moving forward, stakeholders must balance clinical requirements, operational constraints, and sustainability considerations. Decision-makers will need to collaborate across clinical, sterile processing, and procurement functions to evaluate device options holistically, while vendors should prioritize evidence generation, packaging that supports sterile logistics, and clarity in reprocessing protocols. The following sections unpack the pivotal shifts shaping the device category, the regulatory and commercial headwinds ahead, and strategic imperatives for market participants.

How advances in imaging sterilization debates and supply chain diversification are redefining clinical procurement dynamics and product strategies

Over the past several years the sector has experienced transformative shifts that extend beyond incremental product innovation to reshape procurement logic and clinical adoption patterns. Advances in endoscopic imaging and adjunctive technologies have increased the diagnostic yield of tissue sampling, prompting clinicians to demand forceps designs that optimize specimen integrity while minimizing trauma. This technical evolution has driven closer collaboration between device engineers and clinical end users to iterate jaw geometry, shaft flexibility, and tissue retention features that align with specific procedural indications.

Concurrently, the sterilization debate has catalyzed major strategic choices for manufacturers and health systems. The push toward single-use devices in certain procedural settings has been propelled by concerns about cross-contamination, the operational burden of reprocessing, and the variability in sterilization outcomes across facilities. Conversely, innovations in reusable device reprocessing-such as validated autoclave-compatible materials and enhanced cleaning protocols-have sustained demand for reusable options where lifecycle cost and environmental impact are prioritized. Thus, the market now supports parallel pathways where sterilization strategy is a primary determinant of device selection.

Supply chain dynamics have also shifted from geographically concentrated manufacturing to more diversified production strategies. Companies are increasingly investing in regional manufacturing capacities and dual-sourcing critical components to mitigate risk. This realignment has been complemented by digital tools for inventory visibility and demand forecasting, enabling tighter coordination between manufacturers, distributors, and health system purchasing teams. Ultimately, these transformative shifts underscore a transition from purely price-driven procurement toward multi-criteria decision frameworks that integrate clinical performance, reprocessing feasibility, and supply resilience.

Tariff pressures are catalyzing reshored production choices dual sourcing strategies and procurement contingency planning across the value chain

The introduction of tariffs and trade measures has prompted stakeholders to reassess manufacturing footprints, sourcing strategies, and pricing structures. Tariff-driven cost pressures have created incentives for manufacturers to localize production, re-route supply chains, or redesign packaging and components to reduce customs classifications that attract higher duty rates. These operational responses aim to preserve competitiveness while maintaining compliance with evolving import regulations.

For distributors and hospital procurement teams, tariff-induced unit cost variability complicates budgeting and contract negotiations. Purchasing teams are increasingly seeking contractual flexibility, including longer-term agreements with price adjustment clauses tied to tariff changes, and exploring inventory hedging strategies to buffer near-term cost volatility. At the same time, procurement professionals are intensifying supplier qualification activities to include tariff exposure assessments and contingency planning for alternative sourcing.

From a product development perspective, tariffs have accelerated design decisions that reduce reliance on tariff-sensitive inputs and favor modular architectures where high-value components can be sourced regionally. Companies are also evaluating trade compliance as a core element of go-to-market planning, ensuring product labeling, country-of-origin documentation, and classification decisions align with customs requirements. In essence, tariff dynamics are not merely a cost issue; they have become a strategic variable influencing manufacturing location, supplier partnerships, and long-term commercial positioning.

Segment-specific imperatives across product type application end-user and distribution channel that determine clinical adoption cost considerations and channel strategies

Analyzing the market through a segmentation lens reveals differentiated dynamics across product types, clinical applications, end users, and distribution channels that shape adoption pathways and commercial emphasis. Product segmentation distinguishes between reusable and single-use forceps, with reusable options further subdivided into autoclave-compatible instruments and those requiring chemical sterilization, while single-use variants present in both sterile and non-sterile formats. This dichotomy underscores competing priorities: reusable devices are evaluated against lifecycle cost and reprocessing infrastructure, whereas single-use devices are valued for infection control and predictable performance without reprocessing variability.

Application-based segmentation further clarifies clinical demand patterns. Bronchoscopy procedures include both conventional bronchoscopic sampling and endobronchial ultrasound-guided approaches, each imposing distinct requirements for shaft flexibility and specimen capture. Gastrointestinal endoscopy encompasses colonoscopy and esophagogastroduodenoscopy, procedures that place a premium on tissue retrieval efficiency and compatibility with endoscope channel dimensions. Gynecology and urology applications introduce their own anatomical and handling considerations, reinforcing the need for device portfolios that span jaw styles and shaft lengths to service multiple specialties.

End-user segmentation highlights divergent purchasing behaviors among ambulatory surgical centers, clinics, and hospitals. Hospitals tend to centralize procurement decisions, emphasize contractual relationships, and evaluate total cost of ownership across high-volume procedural suites. Ambulatory surgical centers often prioritize devices that streamline turnover and reduce reprocessing burden, creating a propensity toward single-use options when staff capacity for complex sterilization is limited. Clinics, particularly those performing lower procedure volumes, may favor cost-effective reusable devices but require clear reprocessing guidance and support.

Distribution channel segmentation-comprising distributors, hospital procurement channels, and online retail pathways-affects product availability, pricing transparency, and post-sale support. Distributors provide logistical reach and often bundle services such as inventory management and training, while hospital procurement channels leverage framework agreements and supplier performance metrics. Online retail is emerging as a complementary channel for lower-complexity purchases and for rapid replenishment of consumable items, creating pressure on traditional B2B channels to improve service levels and digital ordering capabilities. Collectively, these segmentation dimensions inform where manufacturers should focus product development, evidence generation, and channel investments to maximize clinical uptake and operational alignment.

Regional regulatory procurement and manufacturing nuances across the Americas Europe Middle East Africa and Asia-Pacific that shape adoption and channel approaches

Regional dynamics present distinct regulatory environments, procurement behaviors, and clinical adoption patterns that influence strategic priorities. In the Americas, procurement decisions are frequently influenced by consolidated group purchasing organizations and a strong emphasis on cost-containment balanced with clinical outcomes. The regional market demonstrates rapid uptake of single-use solutions in settings where infection control and streamlined workflows are prioritized, while major health systems maintain a robust interest in reusable technologies where sterilization infrastructure supports high-throughput reprocessing.

Across Europe, the Middle East & Africa, a heterogeneous regulatory and healthcare landscape yields varied adoption timelines and demand profiles. Western European markets often exhibit stringent regulatory scrutiny and well-established sterilization best practices that support both reusable and validated single-use solutions. In contrast, certain markets within the broader region prioritize affordability and supply chain simplicity, leading to selective adoption patterns. Middle East procurement strategies sometimes center on rapid scale-up of procedural capacity, whereas parts of Africa contend with infrastructure limitations that favor simpler device options and robust servicing arrangements.

The Asia-Pacific region is characterized by a combination of high-growth procedural volumes, expanding private healthcare networks, and a strategic push toward local manufacturing. Regional health systems are increasingly focused on procedural efficiency, and regulatory authorities are progressively harmonizing device oversight, which supports the introduction of advanced forceps designs. At the same time, diverse country-level reimbursement and procurement frameworks mean that suppliers must tailor commercial approaches, including local partnerships and targeted evidence generation, to achieve traction across distinct national markets.

Taken together, regional insights underscore the importance of localized regulatory knowledge, adaptive commercial models, and supply chain flexibility. Manufacturers and distributors that align product portfolios, pricing strategies, and service models with regional priorities will be better positioned to capture sustained clinical adoption and long-term contracts.

Competitive differentiation driven by targeted innovation strategic partnerships integrated service offerings and selective acquisitions to accelerate market reach

Competitive dynamics in the biopsy forceps category reflect a blend of product refinement, strategic partnerships, and selective consolidation. Leading device makers are investing in application-specific innovations and evidence generation to differentiate on clinical performance rather than on price alone. Strategic collaborations with clinical centers and endoscopy platform providers have emerged as a common route to accelerate validation and integration, while licensing agreements for proprietary materials or jaw designs enable mid-sized manufacturers to expand their portfolios without duplicative R&D investment.

Mergers and acquisitions remain a tactical lever for acquiring niche technologies, scaling manufacturing capacity, or entering complementary distribution networks. Acquirers typically target assets that provide immediate synergies-such as regional manufacturing sites, validated reprocessing technologies, or specialized forceps geometries tailored to high-value procedures. Meanwhile, smaller entrants often compete by offering targeted solutions for underserved clinical niches or by emphasizing flexible commercial terms and enhanced training packages.

Service and support capabilities are increasingly important differentiators. Companies that provide comprehensive onboarding, sterilization guidance, and on-site training achieve higher clinician loyalty and smoother procurement negotiations. Similarly, robust post-market surveillance and adverse event reporting systems build trust with regulatory bodies and hospital procurement teams. In sum, competitive advantage is accruing to organizations that marry technical product strengths with superior service infrastructure and strategic channel partnerships.

Practical cross-functional measures for manufacturers providers distributors and compliance teams to improve product adoption operational resilience and procurement alignment

Manufacturers should prioritize design-for-reprocessing and design-for-manufacture principles concurrently. By investing in materials and geometries that maintain clinical performance while simplifying cleaning and sterilization, manufacturers can offer dual-use portfolios that address both high-volume hospital settings and resource-constrained outpatient facilities. This dual approach reduces commercial risk and widens addressable clinical segments, enabling more flexible contractual conversations with health systems.

Healthcare providers must adopt cross-functional evaluation teams that include clinical leadership sterile processing professionals and procurement specialists to ensure device selections reflect procedural outcomes and operational realities. Embedding sterile processing input early in the procurement cycle reduces reprocessing failures and downstream service disruptions. In addition, procurement teams should negotiate agreements that incorporate performance metrics, reprocessing support, and training commitments to align supplier incentives with clinical quality goals.

Distributors and channel partners should accelerate digital transformation to offer real-time inventory visibility and automated replenishment tied to usage analytics. Enhanced digital capabilities reduce stockouts and enable just-in-time delivery models that are attractive to high-volume procedural centers. Further, channel partners that bundle training and performance analytics alongside device supply will strengthen relationships with institutional customers and create recurring service revenue streams.

Regulatory and compliance teams need to embed trade and tariff exposure analysis into product launch planning and supplier qualification. Early identification of components subject to elevated duties and proactive redesign or regional sourcing strategies can prevent margin erosion and safeguard supply continuity. Finally, all stakeholders should invest in evidence generation-comparative performance studies, sterilization validation reports, and procedure-specific outcome data-to support adoption conversations and address clinician skepticism with rigorous clinical evidence.

A rigorous multi-method research approach combining targeted primary interviews comprehensive secondary analysis and triangulation to ensure findings are actionable and validated

The research underpinning this report combines qualitative primary engagement with stakeholders and rigorous secondary source synthesis to validate findings and surface actionable insights. Primary research comprised structured interviews with clinical leaders across endoscopy specialties sterile processing managers procurement professionals and distribution executives, complemented by technical consultations with device engineers and regulatory specialists. These dialogues provided context-specific perspectives on device performance, reprocessing workflows, and procurement criteria.

Secondary research included systematic review of regulatory guidance documents, publicly available device labeling and instructions for use, patent literature, and peer-reviewed clinical studies relevant to tissue sampling devices. Where appropriate, material science literature was consulted to assess sterilization compatibility and wear characteristics of common alloys and polymers used in forceps manufacture. Trade compliance sources were reviewed to map tariff classifications and potential exposure risks for cross-border transactions.

Methodologically, the analysis triangulated insights across sources to mitigate single-source bias and employed cross-validation steps including follow-up interviews and member checks with selected stakeholders. Limitations of the study are acknowledged: interview samples, while representative across functions, cannot capture every regional nuance, and rapidly evolving regulatory actions may alter timelines and requirements. Nevertheless, the synthesis reflects robust, multi-source validation and aims to provide decision-useful insights for strategic planning and operational execution.

Concluding implications for manufacturers providers and channel partners emphasizing evidence integration operational alignment and supply chain foresight

In conclusion the biopsy forceps category is undergoing a period of strategic realignment driven by clinical advances sterilization imperatives and supply chain recalibration. Stakeholders must navigate a nuanced tradeoff between single-use convenience and reusable cost efficiency while aligning product choices with procedural needs and reprocessing capacity. Manufacturers that invest in clinically validated designs, clear reprocessing guidance, and regional manufacturing flexibility will be advantaged in contract negotiations and long-term partnerships.

Procurement organizations and clinical teams should institutionalize cross-disciplinary evaluation frameworks to ensure device selection optimizes clinical outcomes and operational workflows. Distributors that enhance digital services and bundle training and analytics will deepen institutional relationships and create durable revenue models. Finally, proactive tariff and trade compliance planning is essential to manage cost volatility and protect margins in an environment of shifting trade policies.

Collectively, these strategic actions will determine which players secure sustained adoption in a market that increasingly values evidence-backed performance, operational compatibility, and supply resilience.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Biopsy Forceps Market, by Product Type
8.1. Reusable
8.1.1. Autoclavable
8.1.2. Chemical Sterilization
8.2. Single Use
8.2.1. Non Sterile
8.2.2. Sterile
9. Biopsy Forceps Market, by Application
9.1. Bronchoscopy
9.1.1. Conventional
9.1.2. Endobronchial Ultrasound
9.2. Gastrointestinal Endoscopy
9.2.1. Colonoscopy
9.2.2. Esophagogastroduodenoscopy
9.3. Gynecology
9.4. Urology
10. Biopsy Forceps Market, by End User
10.1. Ambulatory Surgical Centers
10.2. Clinics
10.3. Hospitals
11. Biopsy Forceps Market, by Distribution Channel
11.1. Distributors
11.2. Hospital Procurement
11.3. Online Retail
12. Biopsy Forceps Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Biopsy Forceps Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Biopsy Forceps Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Biopsy Forceps Market
16. China Biopsy Forceps Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. ACE Medical Devices Pvt. Ltd.
17.6. Anrei medical (hz)co.,Ltd.
17.7. Argon Medical Devices
17.8. Becton, Dickinson and Company
17.9. Boston Scientific Corporation
17.10. Cardinal Health, Inc.
17.11. CONMED Corporation
17.12. Cook Group Incorporated
17.13. FUJIFILM Corporation
17.14. Integer Holdings Corporation
17.15. Integra LifeSciences Corporation
17.16. KARL STORZ SE & Co. KG
17.17. MedGyn Products, Inc.
17.18. Medi-Globe GmbH
17.19. Medline Industries, Inc.
17.20. Medorah Meditek Pvt. Ltd.
17.21. Medtronic PLC
17.22. MICRO-TECH (Nanjing) Co., Ltd,
17.23. Olympus Corporation
17.24. Omnimed Ltd.
17.25. PENTAX Medical by Hoya Corporation
17.26. Scanlan International, Inc.
17.27. Sklar Surgical Instruments
17.28. STERIS Corporation
17.29. Wilson Instruments (SHA) Co., Ltd.
List of Figures
FIGURE 1. GLOBAL BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BIOPSY FORCEPS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BIOPSY FORCEPS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AUTOCLAVABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AUTOCLAVABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AUTOCLAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CHEMICAL STERILIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CHEMICAL STERILIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CHEMICAL STERILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY NON STERILE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY NON STERILE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY NON STERILE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY STERILE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY STERILE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY STERILE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ENDOBRONCHIAL ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ENDOBRONCHIAL ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ENDOBRONCHIAL ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ESOPHAGOGASTRODUODENOSCOPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ESOPHAGOGASTRODUODENOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ESOPHAGOGASTRODUODENOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GYNECOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GYNECOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GYNECOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. EUROPE BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 111. EUROPE BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 113. EUROPE BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 114. EUROPE BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. EUROPE BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. AFRICA BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. AFRICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 127. AFRICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 128. AFRICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 129. AFRICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 130. AFRICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 131. AFRICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 132. AFRICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. AFRICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. ASEAN BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. ASEAN BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 146. ASEAN BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 147. ASEAN BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 148. ASEAN BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 149. ASEAN BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 150. ASEAN BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 151. ASEAN BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. ASEAN BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. GCC BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GCC BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 155. GCC BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 156. GCC BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 157. GCC BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 158. GCC BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 159. GCC BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 160. GCC BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. GCC BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. BRICS BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. BRICS BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 173. BRICS BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 174. BRICS BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 175. BRICS BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 176. BRICS BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 177. BRICS BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 178. BRICS BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. BRICS BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. G7 BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. G7 BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 182. G7 BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 183. G7 BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 184. G7 BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 185. G7 BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 186. G7 BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 187. G7 BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. G7 BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. NATO BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. NATO BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 191. NATO BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 192. NATO BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 193. NATO BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. NATO BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 195. NATO BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 196. NATO BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. NATO BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. CHINA BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. CHINA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 210. CHINA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
TABLE 211. CHINA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
TABLE 212. CHINA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 213. CHINA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
TABLE 214. CHINA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
TABLE 215. CHINA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 216. CHINA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Biopsy Forceps market report include:
  • ACE Medical Devices Pvt. Ltd.
  • Anrei medical (hz)co.,Ltd.
  • Argon Medical Devices
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • CONMED Corporation
  • Cook Group Incorporated
  • FUJIFILM Corporation
  • Integer Holdings Corporation
  • Integra LifeSciences Corporation
  • KARL STORZ SE & Co. KG
  • MedGyn Products, Inc.
  • Medi-Globe GmbH
  • Medline Industries, Inc.
  • Medorah Meditek Pvt. Ltd.
  • Medtronic PLC
  • MICRO-TECH (Nanjing) Co., Ltd,
  • Olympus Corporation
  • Omnimed Ltd.
  • PENTAX Medical by Hoya Corporation
  • Scanlan International, Inc.
  • Sklar Surgical Instruments
  • STERIS Corporation
  • Wilson Instruments (SHA) Co., Ltd.

Table Information